[1] |
Menné T, Johansen JD, Sommerlund M, et al. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema[J]. Contact Dermatitis, 2011,65(1):3⁃12. doi: 10.1111/j.1600⁃0536.2011.01915.x.
|
[2] |
中国医师协会皮肤科医师分会科学委员会 中国医师协会皮肤科医师分会变态反应性疾病专业委员会 中国“手部湿疹科研协作组”. 中国手部湿疹诊疗专家共识(2021版)[J]. 中华皮肤科杂志, 2021,54(1):19⁃26. doi:10.35541/cjd.20200281.
|
[3] |
Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention[J]. J Eur Acad Dermatol Venereol, 2020,34 Suppl 1:4⁃12. doi: 10.1111/jdv.16061.
|
[4] |
Held E, Skoet R, Johansen JD, et al. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter⁃ and intraobserver reliability[J]. Br J Dermatol, 2005,152(2):302⁃307. doi: 10.1111/j.1365⁃2133.2004. 06305.x.
|
[5] |
Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis ⁃ a systematic review[J]. J Dermatolog Treat, 2021,32(1):19⁃28. doi: 10.1080/09546634.2019.1689227.
|
[6] |
Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema⁃⁃short version[J]. J Dtsch Dermatol Ges, 2015,13(1):77⁃85. doi: 10. 1111/ddg.12510.
|
[7] |
Dubin C, Del Duca E, Guttman⁃Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges[J]. Ther Clin Risk Manag, 2020,16:1319⁃1332. doi: 10.2147/TCRM.S292504.
|
[8] |
Voorberg AN, Romeijn G, de Bruin⁃Weller MS, et al. The long⁃term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis⁃52 week results from the Dutch BioDay Registry[J]. Contact Dermatitis, 2022,87(2):185⁃191. doi: 10.1111/cod.14104.
|
[9] |
Zhu GA, Honari G, Ko JM, et al. Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: a case report[J]. JAAD Case Rep, 2020,6(4):296⁃298. doi: 10.1016/j.jdcr. 2020.02.010.
|
[10] |
Loman L, Diercks G, Schuttelaar M. Three cases of non⁃atopic hyperkeratotic hand eczema treated with dupilumab[J]. Contact Dermatitis, 2021,84(2):124⁃127. doi: 10.1111/cod.13693.
|
[11] |
Li Y, Xiao J, Sun Y, et al. Quick treatment of very severe refractory hand and foot eczema with dupilumab: a case report and literature review[J]. J Asthma Allergy, 2023,16:1⁃8. doi: 10.2147/JAA.S399340.
|
[12] |
Li T, Li H, Zhang J. Dupilumab use in non⁃atopic chronic hand eczema: two cases and a review of the literature[J]. Indian J Dermatol Venereol Leprol, 2023:1⁃3. doi: 10.25259/IJDVL_721_2022.
|
[13] |
Politiek K, Loman L, Pas HH, et al. Hyperkeratotic hand eczema: eczema or not?[J]. Contact Dermatitis, 2020,83(3):196⁃205. doi: 10.1111/cod.13572.
|
[14] |
中华医学会皮肤性病学分会特应性皮炎研究中心 中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022,55(6):465⁃470. doi:10. 35541/cjd.20210885.
|